#CTOS2025 is not only about great science, it's also a perfect opportunity for mentorship for trainees and young fellows! Don't miss the 🌅 Sunrise Mentorship Session on Nov 13, 7.00 am ( breakfast and coffee will be served ☕)! Check topics and mentors 🧑‍🏫on the graphic⬇️

⁦⁦@OmicoAustralia⁩ very own ⁦@ProfDMThomas⁩, Cancer Institute NSW Cancer Researcher of the Year. We’re very proud

Kudos to Robert Maki,MD,past President of @ctos, an extraordinary person & med onc for giving the annual Nina Axelrad Lecture. Bob is a truly kind,humble,brilliant clinician-scientist. He has been a beacon for me throughout my career. “What would Bob do?” Congrats! @UCDavisOrtho

The current and future global burden of cancer among adolescents and young adults: a population-based study Out on Lancet Oncology This study quantifies the global burden of cancer among adolescents and young adults (ages 15–39) in 2022 and projects trends through 2050. Using

With >1000 participants and >500 abstracts presented - #CTOS2024 is the biggest platform connecting anyone interested in sarcoma research and therapy. Congratulations to the Program Directors for organizing the meeting @SebioAna @JasonSicklick, Ashleigh Guadagnolo, Odion Binitie

@DCalleMD presenting validation of CINSARC in pts with retroperitoneal sarcoma 🔸CINSARC is prognostic for OS and DFS 🔸CINSARC and Sarculator are correlated 🔸CINSARC do not improve prognostic value of Sarculator @ctosociety #CTOS2024 #CTOSTweeTOS

Most awaited presentation of the year by @schoffski - BRIGTHLINE-1 trial - Brigimadlin 🆚 doxo in 1st line DDLPS ❌negative trial - no improvement in PFS 🔸mPFS 8,4 vs 7.1m HR 0.79 🔸 ORR 22 vs8.6% ⏭️what next? #CTOS2024 @ctosociety

Last week I had the pleasure to visit @TataMemorial Mumbai for the @CancerGridIndia meeting and a subsequent meeting with the great #sarcoma team discussing #precisionmedicine and challenging cases. Common practices, but also different (available) treatment options. Interesting!

We have a vacancy in our AYA Research team. JANE2 project EU. @OlgaHusson @nki https://t.co/GrgzpVjqer

💻Join us online for the EORTC #PatientDays! In the 3rd session on #ClinicalTrials we will discuss the objectives and endpoints of #oncology trials, patient involvement, pragmatic trials, HTA, and patient data control. 👉 https://t.co/nJ6A6ssfli #CancerResearch @Winette_vdGraaf

📰The report from the @EMA_News and @EORTC joint workshop on patient-reported outcomes (PRO) and health-related #QualityofLife (HRQoL) data, held earlier this year, is now available. 👉Read more: https://t.co/tWh4SPwdbL #CancerResearch #GivingVoice2Patients

@HorizonEU @UKRI_News @EuropeanCancer @OlgaHusson @SimoneHanebaum @Janssen_Silvie @NKI_nl @CancerEurope @MAASTROclinic @Unimaas @iknl @EuropeanCancer @EORTC @asdarlington @unisouthampton @rgfeltbower @UniversityLeeds @UniversityManch @GustaveRoussy @CLCCLeonBerard @IstTumori @ILugowska

For more info: https://t.co/1P4GGcAQ4H @HorizonEU @UKRI_News @EuropeanCancer stakeholders meeting

We had an amazing annual GA meeting of @strong_AYA in Maastricht. Great to see the progress made over last year in the different work packages. The #AYA patient advisory board did an inspiring mental exercise with us to stress what Cancer at Young Adult age really means for them

Thank you @jeanyvesblay for your excellent talk at the @cddf_eu - @EORTC workshop #RareCancers You last slides summarized it so well

Join us today at the CDDF workshop for the session on innovative trial designs, chaired by @Winette_vdGraaf, including Denis Lacombe’s lecture on the EORTC TRACE platform at 15:40. Also, don’t miss Winette’s talk on "Path to Access" tomorrow at 10:30. 🔗 https://t.co/D5NgdQu3Ae

So we started with @cddf_eu - @EORTC workshop on #RareCancers in Amsterdam with Francesco Pignatti @EMA_News Patients unmet needs are obvious! How can RWD and trials support evidence together? We need to think in an innovative way.

🔔 📢 We are excited to announce the opening of the @cddf_eu &@EORTC multi-stakeholder workshop on “Innovation and Access in #RareCancers” in Amsterdam today. We welcome all attendees to this unique meeting where open discussion will take place for the next two days. #oncology

Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs https://t.co/rpOhcNsfcU

Such a great pleasure to have @ProfDMThomas from Sydney @UNSW @OmicoAustralia in Amsterdam. Today @NKI_nl he presented his amazing work: “Moving precision oncology from research to clinical practice for rare cancers”. Nice presentations by our PhDstudents #AYA #sarcoma later on